Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
281. |
ECCT/21/05/02 | BFTAF Elderly Switch Study Switching virally suppressed HIV-1 infected elderly adults (age ≥ 60 years) without prior confirmed virological failure from current anti-retroviral regimen to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
View |
282. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
View |
283. |
ECCT/21/05/04 | Multi-nutrients in ADHD Broad spectrum micronutrient supplementation in the management of ADHD symptoms:a clinical trial |
Principal Investigator(s) 1. Maureen Muthoni Njoroge Site(s) in Kenya Kenyatta National Hospital |
View |
284. |
ECCT/21/05/05 | The “EMPATHY” Trial A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. |
Principal Investigator(s) 1. DR LUCAS OTIENO TINA 2. Dr. Bernhards Ragama Ogutu 3. Dr Deborah Chepngeno Langat 4. Dr Videlis Nduba Nduba 5. Dr Janet Oyieko Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county) 3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county) 4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county) |
View |
285. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
View |